-
1
-
-
33745620515
-
Epidemiology of inflammatory breast cancer (IBC)
-
Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2005;22:9-23.
-
(2005)
Breast Dis
, vol.22
, pp. 9-23
-
-
Anderson, W.F.1
Schairer, C.2
Chen, B.E.3
Hance, K.W.4
Levine, P.H.5
-
4
-
-
84877802557
-
Genomic and expression analysis of microdissected inflammatory breast cancer
-
Woodward WA, Krishnamurthy S, YamauchiH, El-Zein R, Ogura D, Kitadai E, et al. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat 2013;138:761-72.
-
(2013)
Breast Cancer Res Treat
, vol.138
, pp. 761-772
-
-
Woodward, W.A.1
Krishnamurthy, S.2
Yamauchi, H.3
El-Zein, R.4
Ogura, D.5
Kitadai, E.6
-
5
-
-
84883483781
-
Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets
-
Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res 2013;19:4685-96.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4685-4696
-
-
Van Laere, S.J.1
Ueno, N.T.2
Finetti, P.3
Vermeulen, P.4
Lucci, A.5
Robertson, F.M.6
-
6
-
-
79955439847
-
Differences in survivalamong womenwith stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study
-
Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. Differences in survivalamong womenwith stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011;117:1819-26.
-
(2011)
Cancer
, vol.117
, pp. 1819-1826
-
-
Dawood, S.1
Ueno, N.T.2
Valero, V.3
Woodward, W.A.4
Buchholz, T.A.5
Hortobagyi, G.N.6
-
7
-
-
84887530130
-
The third international inflammatory breast cancer conference
-
van Golen KL, Cristofanilli M. The third international inflammatory breast cancer conference. Breast Cancer Res 2013;15:318.
-
(2013)
Breast Cancer Res
, vol.15
, pp. 318
-
-
Van Golen, K.L.1
Cristofanilli, M.2
-
8
-
-
79953068258
-
Inflammatory breast cancer: What progress have we made?
-
Dawood S, Cristofanilli M. Inflammatory breast cancer: what progress have we made? Oncology (Williston Park) 2011;25:264-70, 273.
-
(2011)
Oncology (Williston Park)
, vol.25
-
-
Dawood, S.1
Cristofanilli, M.2
-
9
-
-
84893405141
-
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
-
Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 2014;25:384-91.
-
(2014)
Ann Oncol
, vol.25
, pp. 384-391
-
-
Masuda, H.1
Brewer, T.M.2
Liu, D.D.3
Iwamoto, T.4
Shen, Y.5
Hsu, L.6
-
10
-
-
75149145066
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
-
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
-
(2010)
Lancet
, vol.375
, pp. 377-384
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
Manikhas, A.4
Lluch, A.5
Tjulandin, S.6
-
11
-
-
84859158912
-
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): An open-label, single-arm phase 2 study
-
Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012;13:375-84.
-
(2012)
Lancet Oncol
, vol.13
, pp. 375-384
-
-
Pierga, J.Y.1
Petit, T.2
Delozier, T.3
Ferrero, J.M.4
Campone, M.5
Gligorov, J.6
-
12
-
-
84862893473
-
Pathological complete response and accelerated drug approval in early breast cancer
-
Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41.
-
(2012)
N Engl J Med
, vol.366
, pp. 2438-2441
-
-
Prowell, T.M.1
Pazdur, R.2
-
13
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis
-
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72.
-
(2014)
Lancet
, vol.384
, pp. 164-172
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
Mehta, K.4
Costantino, J.P.5
Wolmark, N.6
-
14
-
-
84881239243
-
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
-
Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013;24:1999-2004.
-
(2013)
Ann Oncol
, vol.24
, pp. 1999-2004
-
-
Kim, M.M.1
Allen, P.2
Gonzalez-Angulo, A.M.3
Woodward, W.A.4
Meric-Bernstam, F.5
Buzdar, A.U.6
-
15
-
-
79957601951
-
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups
-
Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011;29:3351-7.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3351-3357
-
-
Untch, M.1
Fasching, P.A.2
Konecny, G.E.3
Hasmuller, S.4
Lebeau, A.5
Kreienberg, R.6
-
16
-
-
84862303759
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
-
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-804.
-
J Clin Oncol
, vol.30
, pp. 1796-1804
-
-
Von Minckwitz, G.1
Untch, M.2
Blohmer, J.U.3
Costa, S.D.4
Eidtmann, H.5
Fasching, P.A.6
-
17
-
-
84856253589
-
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
-
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20.
-
(2012)
N Engl J Med
, vol.366
, pp. 310-320
-
-
Bear, H.D.1
Tang, G.2
Rastogi, P.3
Geyer, C.E.4
Robidoux, A.5
Atkins, J.N.6
-
18
-
-
84856291930
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
-
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309.
-
(2012)
N Engl J Med
, vol.366
, pp. 299-309
-
-
Von Minckwitz, G.1
Eidtmann, H.2
Rezai, M.3
Fasching, P.A.4
Tesch, H.5
Eggemann, H.6
-
19
-
-
84883050174
-
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial
-
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.
-
(2013)
Lancet Oncol
, vol.14
, pp. 933-942
-
-
Cameron, D.1
Brown, J.2
Dent, R.3
Jackisch, C.4
Mackey, J.5
Pivot, X.6
-
20
-
-
84927642996
-
Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
-
Presented at
-
Slamon DJ, Swain SM, Buyse M, Martin M, Geyer CE, Im Y-H, et al.Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Presented at: 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX. Abstract S1-03.
-
2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX
-
-
Slamon, D.J.1
Swain, S.M.2
Buyse, M.3
Martin, M.4
Geyer, C.E.5
Im, Y.-H.6
-
21
-
-
0013209723
-
Inflammatory breast cancer: Clinical features and the role of multimodality therapy
-
Valero V, Buzdar AU, Hortobagyi GN. Inflammatory breast cancer: clinical features and the role of multimodality therapy. Breast J 1996;2:345-52.
-
(1996)
Breast J
, vol.2
, pp. 345-352
-
-
Valero, V.1
Buzdar, A.U.2
Hortobagyi, G.N.3
-
22
-
-
84874667197
-
Unbiased quantitative assessment ofHer-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
-
Ligthart ST, Bidard FC, Decraene C, Bachelot T, Delaloge S, Brain E, et al. Unbiased quantitative assessment ofHer-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2013;24:1231-8.
-
(2013)
Ann Oncol
, vol.24
, pp. 1231-1238
-
-
Ligthart, S.T.1
Bidard, F.C.2
Decraene, C.3
Bachelot, T.4
Delaloge, S.5
Brain, E.6
-
23
-
-
47549095022
-
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer
-
Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurteur M, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008;39:1221-8.
-
(2008)
Hum Pathol
, vol.39
, pp. 1221-1228
-
-
Penault-Llorca, F.1
Abrial, C.2
Raoelfils, I.3
Cayre, A.4
Mouret-Reynier, M.A.5
Leheurteur, M.6
-
24
-
-
84884418164
-
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
-
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de AE, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8.
-
(2013)
Lancet
, vol.382
, pp. 1021-1028
-
-
Goldhirsch, A.1
Gelber, R.D.2
Piccart-Gebhart, M.J.3
De, A.E.4
Procter, M.5
Suter, T.M.6
-
25
-
-
84879780559
-
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial
-
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013;14:741-8.
-
(2013)
Lancet Oncol
, vol.14
, pp. 741-748
-
-
Pivot, X.1
Romieu, G.2
Debled, M.3
Pierga, J.Y.4
Kerbrat, P.5
Bachelot, T.6
-
26
-
-
84899954624
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
-
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;15:640-7.
-
(2014)
Lancet Oncol
, vol.15
, pp. 640-647
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
Lluch, A.4
Tjulandin, S.5
Zambetti, M.6
-
27
-
-
21244466004
-
Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute
-
Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-75.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 966-975
-
-
Hance, K.W.1
Anderson, W.F.2
Devesa, S.S.3
Young, H.A.4
Levine, P.H.5
-
28
-
-
7044272570
-
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
-
Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4067-4074
-
-
Low, J.A.1
Berman, A.W.2
Steinberg, S.M.3
Danforth, D.N.4
Lippman, M.E.5
Swain, S.M.6
-
29
-
-
8544259538
-
Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson Cancer Center
-
Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-9.
-
(1997)
Cancer Chemother Pharmacol
, vol.40
, pp. 321-329
-
-
Ueno, N.T.1
Buzdar, A.U.2
Singletary, S.E.3
Ames, F.C.4
McNeese, M.D.5
Holmes, F.A.6
-
30
-
-
0032883369
-
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: Toxicity and response (PEGASE 02 trial)
-
Viens P, Palangie T, Janvier M, Fabbro M, Roche H, Delozier T, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 1999;81:449-56.
-
(1999)
Br J Cancer
, vol.81
, pp. 449-456
-
-
Viens, P.1
Palangie, T.2
Janvier, M.3
Fabbro, M.4
Roche, H.5
Delozier, T.6
-
31
-
-
33846297680
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
-
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 228-233
-
-
Buzdar, A.U.1
Valero, V.2
Ibrahim, N.K.3
Francis, D.4
Broglio, K.R.5
Theriault, R.L.6
-
32
-
-
77956807651
-
Trastuzumab in primary inflammatory breast cancer (IBC): High pathological response rates and improved outcome
-
Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, et al. Trastuzumab in primary inflammatory breast cancer (IBC): High pathological response rates and improved outcome. Breast J 2010;16:529-32.
-
(2010)
Breast J
, vol.16
, pp. 529-532
-
-
Dawood, S.1
Gong, Y.2
Broglio, K.3
Buchholz, T.A.4
Woodward, W.5
Lucci, A.6
-
33
-
-
84903892630
-
Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy
-
Epub 2nd May
-
Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol 2013; Epub 2nd May.
-
(2013)
Am J Clin Oncol
-
-
Tsai, C.J.1
Li, J.2
Gonzalez-Angulo, A.M.3
Allen, P.K.4
Woodward, W.A.5
Ueno, N.T.6
-
34
-
-
84897445481
-
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data
-
Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
-
(2014)
Lancet Oncol
, vol.15
, pp. 406-414
-
-
Bidard, F.C.1
Peeters, D.J.2
Fehm, T.3
Nole, F.4
Gisbert-Criado, R.5
Mavroudis, D.6
-
35
-
-
57049162148
-
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial
-
Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7004-7010
-
-
Pierga, J.Y.1
Bidard, F.C.2
Mathiot, C.3
Brain, E.4
Delaloge, S.5
Giachetti, S.6
-
36
-
-
84890566328
-
Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study
-
Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int J Breast Cancer 2013;2013:130470.
-
(2013)
Int J Breast Cancer
, vol.2013
, pp. 130470
-
-
Bidard, F.C.1
Belin, L.2
Delaloge, S.3
Lerebours, F.4
Ngo, C.5
Reyal, F.6
-
37
-
-
77951740458
-
Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
-
Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634-45.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2634-2645
-
-
Riethdorf, S.1
Muller, V.2
Zhang, L.3
Rau, T.4
Loibl, S.5
Komor, M.6
-
38
-
-
84887853026
-
Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the neoadjuvant chemotherapy plus targeted treatment breast cancer study "GeparQuinto"
-
Riethdorf S, Mueller V, Mauermann O, Rau T, Loibl S, Eidtmann H, et al. Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the neoadjuvant chemotherapy plus targeted treatment breast cancer study "GeparQuinto". Cancer Res 2013;70(24 Suppl 2):abstract PD01-067.
-
(2013)
Cancer Res
, vol.70
, Issue.24
-
-
Riethdorf, S.1
Mueller, V.2
Mauermann, O.3
Rau, T.4
Loibl, S.5
Eidtmann, H.6
-
39
-
-
84874651590
-
Translating metastasis-related biomarkers to the clinic-progress and pitfalls
-
Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic-progress and pitfalls. Nat Rev Clin Oncol 2013;10:169-79.
-
(2013)
Nat Rev Clin Oncol
, vol.10
, pp. 169-179
-
-
Bidard, F.C.1
Pierga, J.Y.2
Soria, J.C.3
Thiery, J.P.4
-
40
-
-
84886379960
-
Going with the flow: From circulating tumor cells to DNA
-
Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013;5:207ps14.
-
(2013)
Sci Transl Med
, vol.5
, pp. 207ps14
-
-
Bidard, F.C.1
Weigelt, B.2
Reis-Filho, J.S.3
|